OKOlga Victorovna Kurushina

Olga Victorovna Kurushina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olga Victorovna Kurushina has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global practical recommendations from the International Headache Society for the treatment of migraine attacks: an adapted Russian-language version

    by V. V. Osipova, M. A. Vinokurov, A. R. Artemenko, E. R. Lebedeva, A. V. Sergeev, Yu. E. Azimova, A. V. Amelin, L. R. Akhmadeeva, O. B. Doronina, E. V. Ekusheva, et al.

    The article was prepared by experts of the Russian Headache Society (RHS) and represents an adapted Russian-language version of the International Headache Society (IHS) Global practice recommendations for the treatment of migraine attacks, developed taking into account data from systematic reviews, meta-analyses and consensus documents. The recommendations have two levels: optimal – for countries and regions where most medicines are available, and basic – for regions with limited treatment options. Treatment algorithms using non-steroidal anti-inflammatory drugs, triptans, and gepants are presented, along with specific considerations for their use in special patient groups: pregnant women, the elderly, and patients with cardiovascular diseases. Medicines not registered in the Russian Federation and available alternatives are indicated. The adapted recommendations take into account the Russian specifics of drug availability and the clinical recommendations of the Ministry of Health of Russia. Compliance with the recommendations will improve the quality of care for patients with migraine in the Russian Federation.

  • Pharmacological approaches to the correction of autonomic dysfunction in patients with hypertension

    by M.E. Statsenko, M.V. Derevyanchenko, S.V. Fabritskaya, D.S. Guzenko, O.V. Kurushina, A.E. Barulin

    Hypertension is a major contributor to global cardiovascular morbidity and mortality. The autonomic nervous system is essential to homeostasis, and its dysfunction, present in 65—85% of hypertension cases, contributes to cognitive and psycho-autonomic disorders. Objective. To assess the efficacy and safety of sequential therapy with ethyl methylhydroxypyridine succinate (Mexidol, solution for injections and 125 mg tablets) in patients with autonomic dysfunction associated with hypertension. Materials and methods. This prospective, open-label, comparative study enrolled 60 patients aged 40 to 59 years with stage I—II hypertension and autonomic dysfunction (A.M. Vein score >15). The main group (n=30) received standard antihypertensive therapy plus ethyl methylhydroxypyridine succinate, administered intramuscularly for 10 days at 4.0 mL (200 mg), followed by oral administration of 125 mg three times daily for 8 weeks. The control group (n=30) received only standard therapy. Assessments included the A.M. Vein scale, Schulte test, Digital Symbol Substitution Test (DSST), 5-word test, Hospital Anxiety and Depression Scale (HADS), and Clinical Global Impression (CGI). Results. The main group exhibited a statistically significant reduction in the A.M. Vein score by the second visit (p<0.001), followed by further reduction at the third visit (p<0.001). Significant improvements in executive function, as measured by the DSST (p<0.001), and in early memory consolidation, as assessed by the 5-word test (p<0.001), were observed. The HADS scale demonstrated a pronounced anxiolytic and antidepressant effect (p<0.001). According to the CGI scale, improvement at the end of follow-up was observed in 69.5% of patients in the main group, compared to 0% in the control group (p<0.001). Conclusions. Sequential therapy with ethyl methylhydroxypyridine succinate (solution and tablets) is an effective and safe strategy for correcting autonomic, cognitive, and affective disorders in patients with hypertension and autonomic dysfunction.

  • Prognostic Performance of the Falls Scale for Elderly Patients with Nervous System Diseases: А Prospective 90 Day Follow Up Study

    by O.V. Kurushina, S.G. Salikhova, E.E. Vershinina

    INTRODUCTION. Falls in elderly neurological inpatients are a serious clinical challenge. The previously developed Falls Scale for Elderly Patients with Nervous System Diseases (FSND) has shown good psychometric properties, but its ability to predict future falls has not been prospectively assessed. AIM. To determine the prognostic accuracy of the FSND for falls within 90 days after discharge from a neurological hospital and to establish the optimal high‑risk threshold. MATERIALS AND METHODS. A prospective cohort study enrolled 90 patients aged ≥ 65 years (mean age 74.2 ± 6.5 years, 64.4 % women) admitted to a neurological department. All patients completed the FSND (12 binary items, total score 0–12) at admission. Falls were recorded by telephone interview 90 days after discharge. Sensitivity, specificity, predictive values, and the Youden index were calculated for thresholds from 3 to 10 points. ROC analysis, calibration analysis (logistic regression, quintiles of predicted probability), and subgroup analyses (by sex, median age 73 years, and history of falls) were performed. RESULTS AND DISCUSSION. During follow‑up, 42 patients (46.7 %) experienced at least one fall. At the ≥ 6 threshold, sensitivity was 88.1 % (95 % CI 75.0–95.3), specificity 33.3 % (95 % CI 20.4–48.4), positive predictive value 54.3 %, negative predictive value 80.0 %. The maximum Youden index (0.193) was reached at the 6‑point cut‑off. The area under the ROC curve (AUC) was 0.631 (95 % CI 0.51–0.75). The calibration analysis showed a monotonic increase in observed fall rates across quintiles. Sensitivity at the ≥ 6 threshold remained consistently high across subgroups (85.0–90.9 %). The high negative predictive value allows reliable exclusion of high fall risk in patients scoring < 6. CONCLUSION. The FSND demonstrates satisfactory prognostic performance for falls within 90 days after discharge from a neurological hospital and can be used to identify patients who do not require in‑depth assessment. A total score of ≥ 6 is the optimal high‑risk threshold. KEYWORDS: accidental falls, elderly patients, neurological hospital, risk scale, prospective observation, prognostic accuracy

  • Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”

    by A.E. Barulin, M.A. Bakhtadze, O.S. Davydov, F.I. Devlikamova, D.A. Iskra, P.P. Kalinsky, A.E. Karateev, M.L. Kukushkin, O.V. Kurushina, T.I. Nasonova, et al.

    In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.

  • Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, O.V. Kurushina, D.I. Lebedeva, et al.

    Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.

  • Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, V.V. Kim, O.V. Kurushina, et al.

    Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.

  • Open Access

    Post-stroke rehabilitation with a focus on motor and cognitive recovery

    by Aleksandr E. Barulin, O. V. Kurushina, E. P. Chernovolenko

    The relevance of neurorehabilitation research is determined by the high incidence of acute cerebrovascular pathologies, as well as the increasing risk of disability due to residual impairment after a stroke. Severe motor impairment in the limbs, static and gait disorders, and decreased intellectual and memory functions significantly reduce the quality of life of patients and increase the demand for rehabilitation services. The work considers the fundamental principles of neurorehabilitation: early initiation, comprehensiveness, consistency, interdisciplinary approach, and the appropriate combination of drug and non-drug therapies. The main approaches to motor rehabilitation for patients after a stroke are described in detail, and key areas for stroke recurrence prevention are highlighted. Physical rehabilitation methods include kinesitherapy, occupational therapy, gait training, mechanotherapy, neurodevelopment techniques, and motor control restoration using robotic devices based on biofeedback. Various physiotherapeutic approaches (massage, manual therapy, acupuncture, cryotherapy, magnetic and electrical stimulation technologies) are used as adjunctive methods to enhance the effectiveness of motor rehabilitation. Medicines and rehabilitation methods are presented through the prism of evidence-based medicine. Particular importance is given to the correction of cognitive disorders, since their preservation directly affects the success of recovery. Cognitive rehabilitation includes the use of external compensatory strategies, metacognitive training, environmental adaptation with scanning training and multisensory stimulation methods, speech exercises, as well as various computer programs and paper-based methods with training in concentration, rapid selection and switching of attention. The mechanism of action and proven efficacy of choline alfoscerate (Cereton), a multifunctional drug, are demonstrated; its use as part of a comprehensive rehabilitation program significantly improves patients’ cognitive state and enhances their adaptive capacity.

  • Efficacy and safety of ipidacrine (Neuromidin) in patients with diabetic polyneuropathy: results of an open-label comparative study

    by An.B. Danilov, I.V. Guryeva, Yu.V. Karakulova, O.V. Kurushina, A.E. Barulin, F.I. Devlikamova, V.A. Shirokov

    Objective. To assess the efficacy and safety of two ipidacrine (Neuromidin) treatment regimens-a stepwise regimen (intramuscular administration followed by oral therapy) and an oral-only regimen-in patients with type 1 or type 2 diabetes mellitus (DM) and confirmed diabetic polyneuropathy (DPN). Material and methods. In an open-label comparative study, the efficacy and safety of ipidacrine (Neuromidin) were evaluated in 90 patients with DPN receiving conventional antidiabetic therapy. Patients were assigned to three groups of 30 each: 1st — stepwise ipidacrine therapy (initial intramuscular administration followed by oral therapy); 2nd — oral ipidacrine therapy only; 3rd — control group (conventional antidiabetic therapy without ipidacrine). The treatment duration was 60 days. DPN was assessed using the Neuropathy Symptom Score (NSS), Neuropathy Disability Score (NDS), and Total Symptom Score (TSS). The intensity of neuropathic pain was evaluated using the Numeric Rating Scale (NRS). In addition, glycated hemoglobin (HbA1c), cognitive status (Mini-Mental State Examination, MMSE), and electroneuromyography of the peroneal nerve were assessed. Results. Both treatment groups demonstrated a significant improvement in DPN parameters (p<0.001). The stepwise regimen resulted in a more pronounced improvement in NSS (p=0.048). The intensity of neuropathic pain on the NRS significantly decreased in both treatment groups (p<0.001). A significant improvement in glycemic control parameters was observed in the active treatment groups. A mild but statistically significant improvement in cognitive function as assessed by MMSE was also noted (p≤0.04). Electroneuromyography showed positive dynamics in sensory fiber parameters. The safety profile was favorable in both treatment groups. Conclusion. Both ipidacrine regimens demonstrated high efficacy as part of combination therapy for DPN. The stepwise regimen likely provided a faster onset of clinical effect. The safety profile was favorable, and no serious adverse events were observed.


  • Cervicogenic headache: a modern view of diagnosis and treatment

    by A. E. Barulin, A. A. Drushlyakova, V. V. Kolomytsev, O. V. Kurushina

    Cervicogenic headache is a secondary headache that still leaves a number of questions in the discussions of representatives of the medical community, specialists in cephalgology. The article provides up-to-date information on the specifics of etiopathogenesis, clinical manifestations of cervicogenic headache, and features of diagnosis and treatment of this nosology.

  • Open Access

    Innovative approaches to the diagnosis of premenstrual syndrome: the role of the Telegram bot in clinical practice

    by Lyudmila V. Tkachenko, Natalia I. Sviridova, Anna S. Yustus, Olga V. Kurushina

    Background: Premenstrual syndrome (PMS) is a common condition among women of reproductive age and is characterized by pronounced psychoemotional and somatic disturbances that significantly reduce quality of life. According to recent national reviews and clinical studies, PMS remains an underestimated cause of temporary disability and maladaptation, particularly in populations with high cognitive workloads. Pain syndromes – mastalgia, headache, abdominal pain, and musculoskeletal discomfort – represent the leading components of the PMS clinical picture and frequently coexist with emotional lability and sleep disturbances. Despite its high prevalence, PMS remains insufficiently recognized, and standardized tools for pain assessment and dynamic symptom monitoring are still lacking. Objective: To evaluate the effectiveness of the PMS BOT Telegram-based system in the diagnosis, dynamic monitoring, and clinical assessment of PMS-related symptoms. Materials and methods: The study included 158 women of reproductive age: 70 with clinical manifestations of PMS and 88 controls. The PMS BOT chatbot facilitated daily symptom reporting, assessment of pain intensity and psychoemotional disturbances, and the generation of individualized menstrual diaries. Additional diagnostic tools included the Visual Analog Scale (VAS), the PSST questionnaire, algometry, assessment of micronutrient status (B-vitamins, 25-OH vitamin D, ferritin), and measurement of stress-related hormones (cortisol, noradrenaline, adrenaline, serotonin, prolactin). Results: The chatbot improved adherence (80 % active participation for ≥3 cycles) and provided standardized data collection. The most frequent PMS symptoms were emotional lability (97.1 %), insomnia (71.4 %), and muscle tension (61.4 %). The symptom period decreased from 9–10 to 6–8 days. Conclusion: The PMS BOT Telegram chatbot is an effective and accessible digital tool for PMS diagnosis and monitoring, improving quality of care and supporting personalized approaches in gynecology.